Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5270743 | 0.88 | L3MBTL1 (0.52) | L3MBTL1ATMLMNAALDH1A1KDM4E | |
| SCHEMBL5269290 | 0.80 | KMT2A (0.51) | ATMHTR2AHTR2CALDH1A1KDM4E | |
| SCHEMBL5272030 | 0.80 | TACR1 (0.39) | LMNAALDH1A1MAPT | |
| SCHEMBL5268055 | 0.79 | ATM (0.54) | L3MBTL1ATMLMNAALDH1A1KDM4E | |
| SCHEMBL5266579 | 0.78 | L3MBTL1 (0.50) | L3MBTL1ATMLMNAALDH1A1KDM4E | |
| SCHEMBL5270005 | 0.78 | GAA (0.56) | L3MBTL1ATMLMNAALDH1A1KDM4E | |
| SCHEMBL5265964 | 0.77 | SLC6A2 (0.49) | L3MBTL1ATMSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL5271267 | 0.77 | ATM (0.52) | L3MBTL1ATMLMNAHTR2AHTR2C | |
| SCHEMBL5270107 | 0.77 | LMNA (0.61) | L3MBTL1ATMSMN1; SMN2LMNAHTR2A | |
| SCHEMBL5270843 | 0.77 | SLC6A2 (0.49) | L3MBTL1ATMSMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1074539-B1 | Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL CO (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-6894190-B2 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-05-17 | — | — | US | disclosed |
| US-20030232886-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-12-18 | — | — | US | disclosed |
| US-6653507-B2 | Useful intermediate compound of pharmaceuticals for urinary incontinence | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20020143212-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-10-03 | — | — | US | disclosed |
| US-6403832-B1 | MIXING ACID WITH AMINE, PRECIPITATING SALT, AND FILTERING; GOOD OPTICAL PURITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1074539-A2 | Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232886-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | ALDH1A2, CYP8B1, CYP11B2 | L3MBTL1 4870/4885ATM 4581/4885SMN1; SMN2 875/4885 |
| US-20020143212-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | ALDH1A2, ALDH7A1, ALDH18A1 | L3MBTL1 4844/4885ATM 4732/4885SMN1; SMN2 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.